Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26475
Abstract: Steroid‐refractory (SR) acute graft‐versus‐host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the efficacy, safety, prognostic factors, and optimal therapeutic protocol for SR‐aGVHD… read more here.
Keywords: basiliximab; steroid refractory; refractory acute; acute graft ... See more keywords
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26506
Abstract: CD19‐targeted chimeric antigen receptor T (CAR‐T) cells using murine single‐chain variable fragment (scFv) has shown substantial clinical efficacy in treating relapsed/refractory acute lymphoblastic leukemia (R/R ALL). However, potential immunogenicity of the murine scFv domain may… read more here.
Keywords: antigen receptor; refractory acute; relapsed refractory; chimeric antigen ... See more keywords
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3681
Abstract: The preferred salvage treatment for children with relapsed/refractory acute myeloid leukemia (R/R‐AML) remains unclear. The combination of cladribine/Ara‐C/granulocyte‐colony stimulating factor and mitoxantrone (CLAG‐M) shown promising results in adult R/R‐AML. We aim to investigate the efficacy… read more here.
Keywords: relapsed refractory; children relapsed; refractory acute; myeloid leukemia ... See more keywords
Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30604
Abstract: Patients with primary refractory acute lymphoblastic leukemia (PREF ALL) who fail to achieve a complete remission (CR) after ≥2 courses of chemotherapy have a dismal prognosis without undergoing allogeneic hematopoietic cell transplantation (HCT). To the… read more here.
Keywords: acute; refractory acute; primary refractory; transplantation ... See more keywords
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31138
Abstract: Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. read more here.
Keywords: relapsed refractory; refractory acute; myeloid leukemia; acute myeloid ... See more keywords
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35840
Abstract: The treatment of relapsed and/or refractory (R/R) acute myeloid leukemia (AML) remains challenging because of poor responses to chemotherapy. Efforts to improve outcomes have included the use of high‐dose cytarabine in combination with nucleoside analogs,… read more here.
Keywords: cladribine idarubicin; acute myeloid; cytarabine; refractory acute ... See more keywords
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3159
Abstract: Relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) is a genetically complex and heterogeneous disease with a poor prognosis and limited treatment options. Thus, there is an urgent need to develop therapeutic combinations to overcome drug resistance… read more here.
Keywords: myeloid leukemia; refractory acute; relapsed refractory; alvocidib ... See more keywords
The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05892-9
Abstract: Relapsed/refractory acute leukemia (R/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient… read more here.
Keywords: daratumumab based; leukemia; refractory acute; relapsed refractory ... See more keywords
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03792-8
Abstract: BackgroundFLAG (fludarabine, cytarabine, granulocyte colony—stimulating factor) and FLAG-IDA (idarubicin added to standard FLAG) are salvage chemotherapy regimens used for relapsed and refractory acute leukemias. The toxicity of the FLAG-IDA courses is generally more severe than… read more here.
Keywords: relapsed refractory; flag ida; refractory acute; remission ... See more keywords
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02006-7
Abstract: Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+ R/R AML based on… read more here.
Keywords: relapsed refractory; gilteritinib; refractory acute; myeloid leukemia ... See more keywords
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02709-8
Abstract: Expanded therapeutic options are warranted for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations. The present phase 1, multicenter, open-label, dose-escalation and dose-expansion… read more here.
Keywords: relapsed refractory; refractory acute; myeloid leukemia; study ... See more keywords